Navigation Links
New Injectable Collagen Filler Offers Natural Results
Date:7/9/2008

N. DALLAS and PLANO, Texas, July 9 /PRNewswire/ -- SKINTASTIC(TM) Medical and Surgical Rejuvenation Center is pleased to announce the arrival of newly FDA-approved EVOLENCE(R) -- the latest injectable collagen filler in the Skintastic arsenal of little-or-no-downtime beauty treatments.

EVOLENCE(R) boasts immediate, predictable visible results, with little swelling. Less bruising and pain were also reported with EVOLENCE(R) in a comparison study against a popular dermal filler.

EVOLENCE(R) differs from other cosmetic filler giants in its unique formulation; EVOLENCE(R) utilizes highly-purified porcine Type I collagen, regarded as a preferred medical grafting substance due to its nearly identical similarity to human collagen. In comparison to one of the popular, hyaluronic acid, sugar-based gel fillers that are gradually absorbed into the body, EVOLENCE(R) is injected deeper into the dermis where it forms a 3D cellular matrix -- replacing the skin's depleted collagen with new collagen (instead of a collagen substitute), for longer-lasting, natural-looking results. Unlike some other animal-based collagen fillers, EVOLENCE(R) requires no skin-test prior to treatment.

All injectable treatments at Skintastic are performed by cosmetic surgeon Jeffrey Adelglass, MD, FACS. According to Dr. Adelglass, "Skintastic is always searching for new aesthetic treatments offering even longer-lasting, consistently-great results for our cosmetic patients -- treatments that are minimally-invasive and take very little time away from a busy schedule." Most of Skintastic's medical spa treatments can be performed in under an hour. Dr. Adelglass adds that while each of the fillers Skintastic employs offers a unique benefit, a key EVOLENCE(R) advantage is that its immediate visible correction should result in high satisfaction in patients seeking real, natural-appearing collagen replacement.

Experience counts. Jeffrey Adelglass, M.D., F.A.C.S. was the first Texas physician to recently achieve simultaneous Diamond pinnacle-level status as a Botox(R) injector and Triple-Platinum status with Medicis, the makers of Restylane(R) and Perlane(R) injectable fillers. Dr. Adelglass is a member of the Star Program -- a group of cosmetic physicians specially-trained to work with EVOLENCE(R), and an exclusive Black Card member of Radiesse(R) physician injectors. He serves on the scientific advisory boards of most, if not all U.S. dermal filler companies, and on the National Education Foundation for Allergan, instructing other cosmetic physicians to safely administer Botox(R) using his well-honed injection techniques. Dr. Adelglass is also an official training instructor for SmartLipo(TM) laser body sculpting, the DOT Fractional skin resurfacing laser, ArteFill(R) and Juvederm(R) dermal fillers. With his level of experience, it's no wonder that many of the representatives of these companies, with all their available options, select Dr. Adelglass as their own cosmetic physician of choice.

The cost of EVOLENCE(R) is expected to be comparable to that of other currently-popular dermal fillers. Call (972) 620-3223 to be added to a waiting list to receive a complimentary EVOLENCE(R) evaluation (and special introductory offer). EVOLENCE(R)-related questions can also be forwarded to skintastic@skintastic.com. Skintastic is located in the Presbyterian Plano Center for Diagnostics and Surgery at 6020 W. Parker, Suite 400 in Plano, Texas.


'/>"/>
SOURCE SKINTASTIC(TM) Medical and Surgical Rejuvenation Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables
2. Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers
3. Clarity on Cosmetic Injectable Labeling and Use
4. Injectable Antibiotic Protects Against Lyme Disease in Mice
5. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
6. Galderma Completes Tender Offer for CollaGenex
7. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
10. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for SynOss(TM) Synthetic Mineral Bone Graft Material
11. Move Over, Popular Beauty Fillers--Here Comes Evolence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... GA (PRWEB) , ... February 17, 2017 , ... Like ... to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), ... been a key focus area for hospitals across the nation. While many providers are ...
(Date:2/16/2017)... York, New York (PRWEB) , ... February 17, ... ... work and determination. After what took over 10 years of research, development and ... technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ingredients ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection ... patient care, NWH has achieved Magnet® recognition for the second time, ... 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
Breaking Medicine Technology: